The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany-BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) ...
It usually starts with your shower drain looking a little scarier than usual. At first, you tell yourself it’s nothing. Maybe ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
The 4,000-year-old drug, most commonly used to treat pain, prevents certain tumours from forming and spreading across the body – findings that are already changing health policies.
Zacks Small Cap Research on MSN
ASBP: A platform approach to drug delivery with an unconventional path to commercialization
By David Bautz, PhD NASDAQ: ASBP Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is attempting something relatively uncommon ...
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the ...
This is a shame since not only are there plenty of medications on the market that can help manage symptoms, but there are ...
The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today ...
Red-light therapy promises to treat everything from acne and hair loss to depression and chronic pain. Many of these claims ...
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a ...
Racism that fueled the syphilis study still permeates the U.S. health care system, causing disparities in access to medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results